- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07449832
Sperma-epigenoom bij Hodgkin-lymfoom (SPELH)
Multiparametrische detectie en preventieve benaderingen van epigenetische instabiliteit door kankerbehandeling in de mannelijke geslachtslijn.
Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.
We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Advances in cancer treatments are raising new health questions for young survivors of the disease. Cancer itself and DNA-targeted treatments can have long-term effects on reproductive health. In men, spermatogenesis may remain impaired even years after recovery, with consequences for fertility and the health of offspring. It is important to note that sperm production can recover after cancer remission. However, men are advised to wait at least one year after the end of treatment before attempting natural conception, as gamete quality may influence reproductive capacity and offspring health. Yet, regardless of the mode of conception (natural or assisted reproduction), the question of whether a history of cancer and its treatment may affect the health of their offspring remains a fundamental issue that has not yet been clearly answered. In-depth studies are needed for this growing population of young cancer survivors who wish to have healthy children.
Where possible, the use of alkylating agents-known for their long-term systemic harmful effects-is being reduced, and less reprotoxic compounds, such as anthracyclines, are favored. Anthracyclines are widely used to treat various cancers prevalent in young men with a favorable survival prognosis and are classified as weakly reprotoxic (i.e., causing a temporary reduction in sperm count). However, they are suspected of having long-term effects on sperm chromatin and epigenome. The establishment of the sperm epigenome is a complex process resulting from multiple nuclear events during spermatogenesis, including chromatin remodeling and compaction that occur during spermiogenesis. These represent windows of opportunity for alteration by xenobiotics. Furthermore, genomic regions undergoing chromatin rearrangements may be more vulnerable to alterations; if these regions are located on key genes for embryonic development or fetal programming, they may predict adverse effects on offspring. In fact, emerging evidence suggests that sperm epigenetic marks could be used clinically to predict fertility and male-mediated developmental toxicity.
Here, we focus on young men with Hodgkin lymphoma (HL), one of the most commonly diagnosed malignant tumors at a young age, with a good prognosis and low risk of relapse, and for which treatment is well characterized using an anthracycline-containing protocol: doxorubicin. This pathology thus represents a large and relevant population of young cancer survivors who will consider parenthood after cancer. Due to interindividual variability, human studies aiming to determine the effects of chemotherapy must be able to compare samples before and after treatment in the same individual. Such published prospective longitudinal studies are rare and often include very few cases, as they require substantial resources, strong links between oncology and reproduction services, and the ability to follow patients over time, even after the end of oncological treatment. A (non-longitudinal) study of the long-term effects of HL treatments demonstrated persistent abnormalities in chromatin structure and DNA integrity. In the study proposed here, we will analyze epigenetic modifications in sperm from HL patients and their evolution after chemotherapy. We hypothesize that HL and its treatment induce persistent alterations up to 2 years after remission.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Tony MARCHAND, MD, PhD
- Telefoonnummer: +33 02 99 28 42 91
- E-mail: tony.marchand@chu-rennes.fr
Studie Contact Back-up
- Naam: Célia RAVEL, MD, PhD
- Telefoonnummer: +33 02 99 26 59 16
- E-mail: celia.ravel@chu-rennes.fr
Studie Locaties
-
-
-
Rennes, Frankrijk, 35033
- Werving
- Centre Hospitalier Universitaire de Rennes
-
Contact:
- Tony MARCHAND, MD, PhD
- Telefoonnummer: +33 02 99 28 42 91
- E-mail: tony.marchand@chu-rennes.fr
-
Contact:
- Célia RAVEL, MD, PhD
- Telefoonnummer: +33 02 99 26 59 16
- E-mail: celia.ravel@chu-rennes.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Men aged 18 to 45 years
- Diagnosed with Hodgkin lymphoma
- Treatment-naïve to any cytotoxic therapy
- Whose treatment regimen consists of 4 to 6 cycles of ABVD or BrECADD
- Beneficiaries of the French social security system
- Not opposed to participating in research
Exclusion Criteria:
- Patient receiving abdominal radiotherapy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Epigenetic analysis in semen samples
30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes |
5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Alterations in DNA methylation patterns in spermatozoa
Tijdsspanne: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Sperm analysis : Methyl-C Capture Sequencing (MCC-seq) |
Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
|
Alterations of histone 3 H3k4me3 retention sites in spermatozoa
Tijdsspanne: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Sperm analysis : chromatin immunoprecipitation followed by sequencing (ChIP-seq) |
Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Spermogram exam
Tijdsspanne: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
Spermogram examination |
Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
|
|
Identification of known environmental factors impacting spermatogenesis
Tijdsspanne: Month 24 after chemotherapy
|
Patient questionnaire |
Month 24 after chemotherapy
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Géraldine DELBES, PhD, Institut National de la Recherche Scientifique (INRS), Québec, Canada
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- 35RC24_9822_SPELH
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .